Prohance Injection
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
ProHance 279.3 mg/ml, solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Gadoteridol 279.3mg per ml (0.5M)
3 PHARMACEUTICAL FORM
Sterile solution for intravenous injection
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
This medicinal product is for diagnostic use only.
Using Magnetic Resonance Imaging (MRI), ProHance provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood-brain barrier.
ProHance can also be used for whole body MRI including the head, neck, liver, breast, muscoloskeletal system and soft tissue pathologies.
4.2 Posology and method of administration
Posology
Adults
The recommended dose of ProHance for imaging most brain and spinal pathologies is 0.1 mmol/kg. However, doses of 0.3 mmol/kg have been shown to be useful in patients suspected of having cerebral metastases or other poorly enhancing lesions. The recommended dose for whole body MRI is 0.1 mmol/kg.
Paediatric population Children (2 years and above)
The recommended dose of ProHance for brain imaging and spine pathologies is 0.1 mmol/kg (0.2 ml/kg).
ProHance has been used in only a limited number of children aged between 6 months and 2 years. If an MRI procedure must be performed in this group, particular caution should be exercised.
The safety and efficacy of doses higher than 0.1 mmol/kg and sequential or repeat procedures have not been established.
Special Populations
Impaired renal function
ProHance should only be used in patients with severe renal impairment (GFR < 30 ml/min/1.73m2) and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI (see section 4.4). If it is necessary to use ProHance, the dose should not exceed 0.1 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, ProHance injections should not be repeated unless the interval between injections is at least 7 days.
Infants from 6 months to 1 year of age
Due to immature renal function in infants up to 1 year of age, ProHance should only be used in patients 6 to 12 months of age after careful consideration at a dose not exceeding 0.1 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, ProHance injections should not be repeated unless the interval between injections is at least 7 days.
Use of ProHance is not recommended in children less than 6 months of age.
Use for whole body MRI is not recommended in children less than 18 years of age
Elderly (aged 65 years and above)
No dosage adjustment is considered necessary. Caution should be exercised in elderly patients (see section 4.4).
Method of administration
To ensure complete injection of the contrast medium, the injection should be followed by a 5 ml normal saline flush. The imaging procedure should be completed within 1 hour after injecting ProHance.
Caution during injection of any contrast media is necessary to avoid extravasation.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to other gadolinium-based contrast.
ProHance is contraindicated in children under 6 months of age.
4.4 Special warnings and precautions for use
Patients with a history of allergy, drug reactions, or other hypersensitivity-like disorders should be closely observed during the procedure and the contrast medium administration, as well as for the time the physician deems useful given the patient condition.
As with other gadolinium chelates, there have been reports of anaphylactic/anaphylactoid/ hypersensitivity reactions with gadoteridol These reactions manifested with various degrees of severity, including anaphylactic shock or death. They involved one or more body systems, mostly respiratory, cardiovascular and/or mucocutaneous systems.
Anaphylactic shock has been very rarely been reported with the use of gadoteridol
Appropriate drugs and instruments for emergency measures must be readily available.
In patients suffering from epilepsy or brain lesions the likelihood of convulsions during the examination may be increased. Precautions are necessary when examining these patients (e.g. monitoring of the patient) and the equipment and medicinal products needed for the rapid treatment of possible convulsions should be available.
Transitory changes in serum iron (within normal range in the majority of cases) have been observed in some patients after administration of ProHance and these changes were shown not to be clinically significant.
Caution during injection of any contrast media is necessary to avoid extravasation.
Since Gadoteridol is renally cleared from the body, caution should be exercised in patients with severely impaired renal function.
Impaired renal function
Prior to administration of ProHance, it is recommended that all patients are screened for renal dysfunction by obtaining laboratory tests.
There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR < 30 ml/min/1.73m2). Patients undergoing liver transplantation are at particular risk since the incidence of acute renal failure is high in this group. As there is a possibility that NSF may occur with ProHance, it should therefore only be used in patients with severe renal impairment and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI.
Haemodialysis shortly after ProHance administration may be useful at removing ProHance from the body. There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis.
Infants from 6 months to 1 year of age
Due to immature renal function in infants up to 1 year of age, ProHance should only be used in patients 6 to 12 months of age after careful consideration.
Elderly
As the renal clearance of gadoteridol may be impaired in the elderly, it is particularly important to screen patients aged 65 years and older for renal dysfunction.
4.5 Interaction with other medicinal products and other forms of interaction
There are no known drug interactions with Gadoteridol. No clinically significant changes or trends in laboratory tests were seen in clinical trials with ProHance®.
4.6 Fertility, pregnancy and lactation
Fertility
There are no fertility data.
Pregnancy
There are no data from the use of gadoteridol in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). ProHance should not be used during pregnancy unless the clinical condition of the woman requires use of gadoteridol.
Lactation
Gadolinium containing contrast agents are excreted into breast milk in very small amounts (see section 5.3). At clinical doses, no effects on the infant are anticipated due to the small amount excreted in milk and poor absorption from the gut. Continuing or discontinuing breast feeding for a period of 24 hours after administration of ProHance, should be at the discretion of the doctor and lactating mother.
4.7 Effects on Ability to Drive and Use Machines
On the basis of the pharmacokinetic and pharmacodynamic profiles, no or negligible influence is expected with the use of ProHance on the ability to drive or use machines.
4.8 Undesirable effects
The accepted safety considerations and procedures that are required for Magnetic Resonance Imaging are applicable when ProHance is used for contrast enhancement. The following adverse reactions have been reported with ProHance. Adverse reactions from clinical trials have been included with an indication of the frequency. Adverse reactions from spontaneous reporting are included with the frequency “not known”. There were no adverse reactions with an incidence greater than 2%.
|
System Organ Class |
Adverse Reactions | |||
|
Common (>1/100 -<1/10) |
Uncommon (>1/1000 - <1/100) |
Rare (>1/10,000 - <1/1000) |
Not known ( cannot be estimated from the available data) | |
|
Immune system disorders |
Anaphylactic/anaphylactoid reactions*** | |||
|
Psychiatric disorders |
anxiety | |||
|
Nervous system disorders |
headache, paraesthesia, dizziness, taste disturbance |
mental impairment, abnormal coordination, convulsion |
loss of consciousness, coma, vasovagal reactions* | |
|
Eye disorders |
increased lacrimation | |||
|
Ear and labyrinth disorders |
tinnitus | |||
|
Cardiac disorders |
nodal arrhythmia |
cardiac arrest | ||
|
Vascular disorders |
flushing, hypotension | |||
|
Respiratory, thoracic and mediastinal disorders |
laryngospasm, dyspnoea, rhinitis, cough, apnea, wheezing |
respiratory arrest , pulmonary oedema | ||
|
Gastrointestinal disorders |
nausea |
dry mouth, vomiting |
abdominal pain, tongue oedema, oral pruritus, gingivitis, loose stools | |
|
Skin and subcutaneous tissue disorders |
pruritus, rash, urticaria |
oedema face | ||
|
Musculoskeletal and connective tissue disorders |
musculoskeletal stiffness | |||
|
Renal and urinary system |
acute renal failure** | |||
|
General disorders and administration site conditions |
injection site pain, injection site reaction****, asthenia |
chest pain, pyrexia | ||
|
Investigations |
heart rate increased | |||
Description of selected adverse reactions *Vasovagal reactions
Vasovagal reactions, rarely leading to vasovagal syncope have been reported during or immediately after ProHance administration. The condition is often related to emotional distress or painful/unpleasant stimuli (e.g. needle puncture for IV placement). Symptoms commonly experienced include nausea, dizziness and diaphoresis.
In severe cases possibly leading to syncope, patients are usually pale and diaphoretic with altered state of consciousness and bradycardia. In addition patients could frequently experience apprehension, restlessness, faintness and salivary hypersecretion. Proper recognition of this reaction and differential diagnosis with hypersensitivity/anaphylactoid reaction is vital in order to apply the appropriate treatment measures to revert the vagal stimulation.
**Acute renal failure
Cases of acute renal failure have been reported in patients with pre-existing severe renal impairment.
***Anaphylactic/anaphylactoid reactions As with other gadolinium chelates, there have been reports of anaphylactic/anaphylactoid/ hypersensitivity reactions with gadoteridol. These reactions manifested with various degrees of severity, including anaphylactic shock or death. They involved one or more body systems, mostly respiratory, cardiovascular and/or mucocutaneous systems. Commonly reported symptoms include throat tightness, throat irritation, dyspnoea, chest discomfort, feeling hot, dysphagia, burning sensation, oedema in pharynx or larynx, and hypotension.
**** Injection site reactions are mainly characterised by local pain, erythema or swelling, and in some cases they are a consequence of an extravasation.
Isolated cases of nephrogenic systemic fibrosis (NSF) have been reported with ProHance, most of which were in patients co-administered other gadolinium-containing contrast agents (see section 4.4).
Paediatric Patients
The ProHance safety profile is similar in children and adults.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
There have been no cases of overdose reported to date, consequently, neither signs nor symptoms of overdosage have been identified. In the event of overdosage occurring, the patient should be observed and treated symptomatically.
ProHance can be removed by haemodialysis. However there is no evidence that haemodialysis is suitable for prevention of nephrogenic systemic fibrosis (NSF).
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: magnetic resonance imaging contrast media, ATC code: V08CA04
Mechanism of action Gadoteridol is a non-ionic paramagnetic contrast medium for Magnetic Resonance Imaging.
When placed in a magnetic field, gadoteridol decreases T1 relaxation times in targeted areas. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences.
Pharmacodynamic effects
However, disruption of the blood-brain barrier or normal vascularity allows penetration of gadoteridol into lesions such as neoplasms, abscesses, and subacute infarcts.
5.2 Pharmacokinetic properties
Distribution
The pharmacokinetics of intravenously administered gadoteridol in normal subjects conforms to a two- compartment open model with mean distribution and elimination half-lives (reported as mean ± SD) of about 0.20 ± 10.04 hours and 1.57 ± 10.08 hours, respectively.
Elimination
Gadoteridol is exclusively eliminated in the urine with 94.4 ± 4.8% (mean ± SD) of the dose excreted within 24 hours post injection. There is no detectable biotransformation or decomposition of gadoteridol.
The renal and plasma clearance rates (1.41 ± 0.33 ml/min/kg and 1.50 ± 0.35 ml/min/kg, respectively) of gadoteridol are essentially identical, indicating no alteration in elimination kinetics on passage through the kidneys and that the drug is essentially cleared through the kidney. The volume of distribution (204 ± 58 ml 1 kg) is equal to that of extra cellular water, and clearance is similar to that of substances which are subject to glomerular filtration.
No serum protein binding was detected in rats.
5.3 Preclinical safety data
Preclinical data indicate no additional risks for humans based on conventional studies of safety pharmacology, repeated dose toxicity or genotoxicity. Carcinogenicity studies have not been conducted.
Reproduction toxicity studies gave no indication of teratogenic potential. Rats and rabbits that received gadoteridol for 12-13 days during gestation showed an increase in post-implantation loss / abortion at doses 20-33 times the maximum human dose of 0.3mmol/kg/day. The offspring of rats treated at this dose also showed an increased spontaneous motor activity.
6 PHARMACEUTICAL PARTICULARS
6.1
List of excipients
Calteridol Calcium Tromethamine Hydrochloric Acid Sodium Hydroxide Water for Injections
6.2 Incompatibilities
ProHance® should not be admixed with any other drug.
6.3 Shelf life
36 months.
6.4 Special precautions for storage
Store at room temperature (15-30°C.), protect from light. Frozen syringes should be discarded.
6.5 Nature and contents of container
Syringes: Type I glass syringes with rubber stoppers and polypropylene plunger rods containing 5,10, 15 or 17 ml.
6.6 Special precautions for disposal
a. Screw the threaded tip of the plunger rod clockwise into the cartridge plunger and push forward a few millimeters to break any friction between the cartridge plunger and syringe barrel.
b. Holding syringe erect, aseptically remove the rubber cap from the tip of the syringe and attach either a sterile, disposable needle or tubing with a compatible luer lock using a push-twist action.
c. Hold the syringe erect and push plunger forward until all the air is evacuated and fluid either appears at the tip of the needle or the tubing is filled. Following the usual aspiration procedure, complete the injection. To ensure complete delivery of the contrast medium, the injection should be followed by a normal saline flush.
d. Properly dispose of the syringe and any other material used.
The peel-off tracking label on the syringes should be stuck onto the patient record to enable accurate recording of the gadolinium contrast agent used. The dose used should also be recorded. If electronic patient records are used, the name of the product, the batch number and the dose should be entered into the patient record.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Bracco International B.V.
Strawinskylaan 3051 1077 ZX Amsterdam The Netherlands
8 MARKETING AUTHORISATION NUMBER(S)
PL 14447/0002
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
28 February 1997 / 26 March 2003
10 DATE OF REVISION OF THE TEXT
02/06/2016